A Phase 2 interventional study of Efruxifermin and Placebo in NASH - Nonalcoholic Steatohepatitis, sponsored by Akero Therapeutics, Inc. Completed at 55 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-06-18.
Sponsored by Akero Therapeutics, Inc (part of Novo Nordisk A/S) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Non-alcoholic Fatty Liver Disease by Novo Nordisk A/S — 1 open to participants now, 4 under way, 3 of them phase 3. Non-alcoholic Fatty Liver Disease · Novo Nordisk A/S.
Among the 18 studies in Non-alcoholic Fatty Liver Disease by Novo Nordisk A/S, this one is the 7th largest by enrollment of the 17 interventional ones that give a count, is one of 5 that started in 2021, is one of 6 in phase 2, and was the 7th registered.
1,617 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.
Browse Non-alcoholic Fatty Liver Disease studies →1 of the 18 studies in Non-alcoholic Fatty Liver Disease by Novo Nordisk A/S is open now, in 12 countries. Recruiting first, the newest first:
Akero Therapeutics, Inc · Sites in United States, Argentina, Australia and 20 more countries
Ages 18–80
By country, each count listing its studies:
Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 7 · Phase 3 3
First in 2016; this study’s year is marked. 5 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 128 is above the median of 60 across 1,176 interventional studies indexed under Non-alcoholic Fatty Liver Disease.
Median enrollment 71 across the 17 interventional studies, 675 across the 1 observational. Of the 14 that completed or were terminated, 6 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Akero Therapeutics, Inc, one of the names counted as Novo Nordisk A/S. Under that name alone:
Akero Therapeutics, Inc is the lead sponsor of 6 studies on the registry; 2 are open to participants now.
1 of the studies in Non-alcoholic Fatty Liver Disease by Novo Nordisk A/S that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07214870Novo Nordisk A/SA Research Study of a Potential New Medicine (NNC4005-0001) for Liver Disease in Adult Participants With Increased Body Weight and Liver Fat | 2027-05-14 |
Add it to your calendar (.ics) → With an account.
Among the 18 studies in Non-alcoholic Fatty Liver Disease by Novo Nordisk A/S, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study in non-cirrhotic subjects with biopsy-proven F2 - F3 NASH.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
-proven NASH. Must have had a liver biopsy obtained ≤ 180 days prior to randomization with fibrosis stage 2 to 3 and a non-alcoholic fatty liver disease (NAFLD) activity score (NAS) of ≥ 4 with at least a score of 1 in each of the following NAS components:
Exclusion Criteria:
Other inclusion and exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
double-blind, once-weekly subcutaneous injection
Drug: Placebo
double-blind, once-weekly subcutaneous injection
Drug: Efruxifermin
double-blind, once-weekly subcutaneous injection
Drug: Efruxifermin
subcutaneous injection
Also known as: EFX
subcutaneous injection
Effect of Efruxifermin (EFX) vs Placebo on Fibrosis Regression in Participants With Metabolic Dysfunction-associated Steatohepatitis (MASH)-Associated Stage 2 or 3 Fibrosis (F2 or F3)
Proportions of subjects in EFX vs placebo groups with improvement in liver fibrosis, defined as ≥ 1 stage NASH Clinical Research Network \[CRN\] fibrosis score (score ranges from 0 to 4, increasing with fibrosis severity), and no worsening of steatohepatitis (no increase in NASH Activity Score \[NAS\], which ranges from 0 to 8 and is the sum of scores of steatosis, lobular inflammation, and hepatocyte ballooning), at Week 24
Time frame: 24 Weeks
Proportion of Subjects Who Achieve Improvement in Liver Fibrosis ≥ 1 Stage and no Worsening of Steatohepatitis at Week 96
Proportions of subjects in EFX vs baseline groups who achieve improvement in liver fibrosis (decrease of ≥ 1 stage in NASH CRN fibrosis score) and no worsening of steatohepatitis (no increase in NAS for ballooning, inflammation, or steatosis) at Week 96
Time frame: 96 Weeks
Proportion of Subjects Who Achieve Resolution of Steatohepatitis and no Worsening of Liver Fibrosis at Week 24 and Week 96
Proportions of subjects in EFX vs placebo groups who achieve resolution of steatohepatitis (defined as a NAS of 0-1 for inflammation, 0 for ballooning, and any value for steatosis) and no worsening of liver fibrosis (determined by the NASH CRN criteria)
Time frame: 24 and 96 weeks
Proportion of Subjects Who Achieve Improvement in Liver Fibrosis ≥ 1 Stage at Week 24 and Week 96
Proportion of subjects in EFX vs placebo groups who achieve improvement in liver fibrosis (decrease ≥ 1 stage in NASH CRN fibrosis score)
Time frame: 24 and 96 Weeks
Change From Baseline in Hepatic Fat Fraction in EFX vs Placebo Groups
Change from baseline in hepatic fat fraction, measured by magnetic resonance imaging proton-density fat fraction (MRI-PDFF): Week 24 and Week 96 MRI-PDFF Analysis Set
Time frame: 24 and 96 Weeks
Change From Baseline in Lipoproteins at Week 24 and Week 96
Change from baseline of lipoproteins (triglycerides, Non-HDL-C, HDL-C and LDL-C) in EFX vs placebo groups
Time frame: 24 and 96 weeks
Change From Baseline of Hemoglobin A1c (Glycated Hemoglobin, HbA1c) at Week 24 and Week 96
Change from baseline in hemoglobin A1c (glycated hemoglobin, HbA1c) in EFX vs placebo groups
Time frame: 24 Weeks, 96 Weeks
Change From Baseline in C-peptide at Week 24 and Week 96
Change from baseline in C-peptide in EFX vs placebo groups
Time frame: 24 Weeks, 96 Weeks
Change From Baseline in Adiponectin at Week 24 and Week 96
Change from baseline in adiponectin in EFX vs placebo groups
Time frame: 24 Weeks, 96 Weeks
Change From Baseline in Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) at Week 24 and Week 96
Change from baseline in Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) in EFX vs placebo groups The Homeostatic Model Assessment of Insulin Resistance, HOMA-IR, is a calculated index that estimates insulin resistance based on fasting glucose and insulin levels. Higher values indicate greater insulin resistance. \< 1.0: Normal insulin sensitivity 1.0-1.9: Mild insulin resistance 2.0-2.9: Moderate insulin resistance \> 2.9: Severe insulin resistance
Time frame: 24 Weeks, 96 Weeks
Change From Baseline in Enhanced Liver Fibrosis (ELF) Score at Week 24 and Week 96
Change from Baseline in Enhanced Liver Fibrosis (ELF) Score in EFX vs placebo groups The Enhanced Liver Fibrosis (ELF) score is a non-invasive blood test that assesses the risk of liver fibrosis and its progression. Lower risk (\<9.8): Suggests a lower risk of advanced liver fibrosis. Mid risk (9.8-11.2): Indicates a moderate risk of disease progression. Higher risk (≥11.3): Suggests a higher risk of developing cirrhosis or liver-related events
Time frame: 24 and 96 Weeks
Change From Baseline in N-terminal Type III Collagen Propeptide (Pro-C3) at Week 24 and Week 96
Change from Baseline in N-terminal Type III Collagen Propeptide (Pro-C3) in EFX vs placebo groups
Time frame: 24 and 96 Weeks
Change From Baseline in Collagen III Neo-Peptide (C3M) at Week 24 and Week 96
Change from Baseline in Collagen III Neo-Peptide (C3M) in EFX vs placebo groups
Time frame: 24 and 96 Weeks
Change From Baseline in NIS4 Score at Week 24 and Week 96
Change from Baseline in NIS4 score in EFX vs placebo groups NIS4 scores range from 0 to 1 and are calculated by combining the results of four individual biomarker assays \[miR34a-5p, α2-macroglobulin (A2M), YKL-40 and HbA1c\] each of which contributes to the test's ability to detect liver inflammation and/or fibrosis. \>0.63: Higher risk of NASH or advanced fibrosis 0.37-0.63: Moderate risk, and additional testing may be considered \<0.36: Lower risk of of NASH or advanced fibrosis
Time frame: 24 and 96 Weeks
Change in Body Weight at Week 24 and Week 96
Change from baseline in body weight (kg) in EFX vs placebo groups
Time frame: 24 and 96 weeks
Change From Baseline in Liver Stiffness (kPa) at Week 24 and Week 96
Change from Baseline in Liver Stiffness Evaluated by FibroScan in EFX vs placebo groups at Week 24 and Week 96: Full Analysis Set
Time frame: 24 and 96 weeks
| Milestone | Placebo | Efruxifermin 28 mg | Efruxifermin 50 mg |
|---|---|---|---|
| Started | 43 | 42 | 43 |
| Started study drug | 43 | 40 | 43 |
| Completed week 96 treatment | 34 | 26 | 27 |
| Discontinued treatment | 9 | 16 | 16 |
| Completed week 24 visit | 42 | 37 | 36 |
| Completed | 34 | 27 | 27 |
| Not completed | 9 | 15 | 16 |
| Withdrew: Adverse event | 0 | 4 | 3 |
| Withdrew: Clinical outcomes endpoint (excluding death) | 1 | 3 | 3 |
| Withdrew: Required use of a prohibited medication | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 7 | 5 | 4 |
| Withdrew: At the discretion of the investigator or sponsor for noncompliance | 1 | 0 | 3 |
| Withdrew: Lost to follow-up | 0 | 2 | 3 |
Proportions of subjects in EFX vs placebo groups with improvement in liver fibrosis, defined as ≥ 1 stage NASH Clinical Research Network \[CRN\] fibrosis score (score ranges from 0 to 4, increasing with fibrosis severity), and no worsening of steatohepatitis (no increase in NASH Activity Score \[NAS\], which ranges from 0 to 8 and is the sum of scores of steatosis, lobular inflammation, and hepatocyte ballooning), at Week 24
| Participants | Placebo | Efruxifermin 28 mg | Efruxifermin 50 mg |
|---|---|---|---|
| Effect of Efruxifermin (EFX) vs Placebo on Fibrosis Regression in Participants With Metabolic Dysfunction-associated Steatohepatitis (MASH)-Associated Stage 2 or 3 Fibrosis (F2 or F3) | 8 | 15 | 14 |
Proportions of subjects in EFX vs baseline groups who achieve improvement in liver fibrosis (decrease of ≥ 1 stage in NASH CRN fibrosis score) and no worsening of steatohepatitis (no increase in NAS for ballooning, inflammation, or steatosis) at Week 96
| Participants | Placebo | Efruxifermin 28 mg | Efruxifermin 50 mg |
|---|---|---|---|
| Proportion of Subjects Who Achieve Improvement in Liver Fibrosis ≥ 1 Stage and no Worsening of Steatohepatitis at Week 96 | 8 | 12 | 21 |
Proportions of subjects in EFX vs placebo groups who achieve resolution of steatohepatitis (defined as a NAS of 0-1 for inflammation, 0 for ballooning, and any value for steatosis) and no worsening of liver fibrosis (determined by the NASH CRN criteria)
| Participants | Placebo | Efruxifermin 28 mg | Efruxifermin 50 mg |
|---|---|---|---|
| Week 24 | 6 | 18 | 26 |
| Week 96 | 8 | 16 | 16 |
Proportion of subjects in EFX vs placebo groups who achieve improvement in liver fibrosis (decrease ≥ 1 stage in NASH CRN fibrosis score)
| Participants | Placebo | Efruxifermin 28 mg | Efruxifermin 50 mg |
|---|---|---|---|
| Week 24 | 9 | 15 | 14 |
| Week 96 | 9 | 12 | 21 |
Change from baseline in hepatic fat fraction, measured by magnetic resonance imaging proton-density fat fraction (MRI-PDFF): Week 24 and Week 96 MRI-PDFF Analysis Set
| percentage hepatic fat | Placebo | Efruxifermin 28 mg | Efruxifermin 50 mg |
|---|---|---|---|
| Week 24 | -1.9 ± 0.78 | -8.8 ± 0.84 | -11.2 ± 0.86 |
| Week 96 | -2.5 ± 0.89 | -6.3 ± 1.01 | -8.3 ± 1.00 |
Change from baseline of lipoproteins (triglycerides, Non-HDL-C, HDL-C and LDL-C) in EFX vs placebo groups
| mg/dL | Placebo | Efruxifermin 28 mg | Efruxifermin 50 mg |
|---|---|---|---|
| Change from baseline in triglycerides (mg/dL) at Week 24 | 10.5 ± 6.82 | -41.1 ± 7.26 | -44.7 ± 7.20 |
| Change from baseline in triglycerides (mg/dL) at Week 96 | 16.1 ± 7.69 | -26.9 ± 8.63 | -31.7 ± 8.54 |
| Change from baseline in HDL cholesterol (mg/dL) at Week 24 | -0.9 ± 1.09 | 10.1 ± 1.16 | 11.5 ± 1.15 |
| Change from baseline in HDL cholesterol (mg/dL) at Week 96 | 1.3 ± 1.43 | 7.3 ± 1.59 | 10.7 ± 1.57 |
| Change from baseline in LDL cholesterol (mg/dL) at Week 24 | 4.0 ± 3.47 | -10.4 ± 3.7 | -9.6 ± 3.69 |
| Change from baseline in LDL cholesterol (mg/dL) at Week 96 | -1.3 ± 4.74 | -1.2 ± 5.29 | -1.4 ± 5.23 |
| Change from baseline in non-HDL cholesterol (mg/dL) at Week 24 | 6.1 ± 3.83 | -16.6 ± 4.08 | -16.6 ± 4.05 |
| Change from baseline in non-HDL cholesterol (mg/dL) at Week 96 | 1.5 ± 5.31 | -4.5 ± 5.92 | -6.7 ± 5.86 |
Change from baseline in hemoglobin A1c (glycated hemoglobin, HbA1c) in EFX vs placebo groups
| % glycated hemoglobin | Placebo | Efruxifermin 28 mg | Efruxifermin 50 mg |
|---|---|---|---|
| Change from baseline in hemoglobin A1C (HbA1c, %) at Week 24 | -0.0 ± 0.12 | -0.3 ± 0.12 | -0.4 ± 0.12 |
| Change from baseline in hemoglobin A1C (HbA1c, %) at Week 96 | -0.0 ± 0.22 | 0.0 ± 0.24 | 0.2 ± 0.24 |
Change from baseline in C-peptide in EFX vs placebo groups
| ng/mL | Placebo | Efruxifermin 28 mg | Efruxifermin 50 mg |
|---|---|---|---|
| Change from baseline in C-Peptide at Week 24 | 0.0 ± 0.19 | -0.8 ± 0.20 | -1.2 ± 0.19 |
| Change from baseline in C-Peptide at Week 96 | -0.2 ± 0.22 | -0.4 ± 0.25 | -1.0 ± 0.25 |
Change from baseline in adiponectin in EFX vs placebo groups
| ng/mL | Placebo | Efruxifermin 28 mg | Efruxifermin 50 mg |
|---|---|---|---|
| Change from baseline in adiponectin at Week 24 | 296.4 ± 312.56 | 1411.5 ± 333.48 | 3088.8 ± 333.82 |
| Change from baseline in adiponectin at Week 96 | 531.5 ± 416.93 | 975.3 ± 459.40 | 2018.3 ± 458.91 |
Change from baseline in Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) in EFX vs placebo groups The Homeostatic Model Assessment of Insulin Resistance, HOMA-IR, is a calculated index that estimates insulin resistance based on fasting glucose and insulin levels. Higher values indicate greater insulin resistance. \< 1.0: Normal insulin sensitivity 1.0-1.9: Mild insulin resistance 2.0-2.9: Moderate insulin resistance \> 2.9: Severe insulin resistance
| units on a scale | Placebo | Efruxifermin 28 mg | Efruxifermin 50 mg |
|---|---|---|---|
| Change from baseline in Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) at Week 24 | 0.7 ± 1.09 | -4.7 ± 1.19 | -5.6 ± 1.14 |
| Change from baseline in Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) at Week 96 | -1.3 ± 0.87 | -4.1 ± 1.01 | -5.5 ± 0.99 |
Change from Baseline in Enhanced Liver Fibrosis (ELF) Score in EFX vs placebo groups The Enhanced Liver Fibrosis (ELF) score is a non-invasive blood test that assesses the risk of liver fibrosis and its progression. Lower risk (\<9.8): Suggests a lower risk of advanced liver fibrosis. Mid risk (9.8-11.2): Indicates a moderate risk of disease progression. Higher risk (≥11.3): Suggests a higher risk of developing cirrhosis or liver-related events
| score on a scale | Placebo | Efruxifermin 28 mg | Efruxifermin 50 mg |
|---|---|---|---|
| Change from baseline in ELF Score at Week 24 | 0.1 ± 0.10 | -0.6 ± 0.10 | -0.7 ± 0.10 |
| Change from baseline in ELF Score at Week 96 | -0.1 ± 0.14 | -0.7 ± 0.16 | -0.8 ± 0.16 |
Change from Baseline in N-terminal Type III Collagen Propeptide (Pro-C3) in EFX vs placebo groups
| ng/mL | Placebo | Efruxifermin 28 mg | Efruxifermin 50 mg |
|---|---|---|---|
| Change from baseline in N-terminal Type III Collagen Propeptide (Pro-C3) GEN2 at Week 24 | -2.7 ± 6.99 | -51.1 ± 7.37 | -53.9 ± 7.37 |
| Change from baseline in N-terminal Type III Collagen Propeptide (Pro-C3) GEN2 at Week 96 | -17.2 ± 7.87 | -40.2 ± 8.89 | -50.5 ± 8.92 |
Change from Baseline in Collagen III Neo-Peptide (C3M) in EFX vs placebo groups
| ng/mL | Placebo | Efruxifermin 28 mg | Efruxifermin 50 mg |
|---|---|---|---|
| Change from baseline in Collagen III Neo-Peptide (C3M) (ng/mL) at Week 24 | 0.2 ± 0.35 | -0.8 ± 0.37 | -1.1 ± 0.38 |
| Change from baseline in Collagen III Neo-Peptide (C3M) (ng/mL) at Week 96 | 3.1 ± 0.71 | 3.3 ± 0.80 | 4.4 ± 0.80 |
Change from Baseline in NIS4 score in EFX vs placebo groups NIS4 scores range from 0 to 1 and are calculated by combining the results of four individual biomarker assays \[miR34a-5p, α2-macroglobulin (A2M), YKL-40 and HbA1c\] each of which contributes to the test's ability to detect liver inflammation and/or fibrosis. \>0.63: Higher risk of NASH or advanced fibrosis 0.37-0.63: Moderate risk, and additional testing may be considered \<0.36: Lower risk of of NASH or advanced fibrosis
| score on a scale | Placebo | Efruxifermin 28 mg | Efruxifermin 50 mg |
|---|---|---|---|
| Change from baseline in NIS-4 score at Week 24 | -0.0 ± 0.03 | -0.3 ± 0.04 | -0.3 ± 0.04 |
| Change from baseline in NIS-4 score at Week 96 | -0.1 ± 0.05 | -0.2 ± 0.05 | -0.3 ± 0.05 |
Change from baseline in body weight (kg) in EFX vs placebo groups
| kg | Placebo | Efruxifermin 28 mg | Efruxifermin 50 mg |
|---|---|---|---|
| Change from Baseline in Body Weight (kg) at Week 24 | -0.6 ± 0.82 | -0.2 ± 0.86 | -3.0 ± 0.85 |
| Change from Baseline in Body Weight (kg) at Week 96 | -1.5 ± 1.40 | -0.3 ± 1.53 | -3.5 ± 1.52 |
Change from Baseline in Liver Stiffness Evaluated by FibroScan in EFX vs placebo groups at Week 24 and Week 96: Full Analysis Set
| kPa | Placebo | Efruxifermin 28 mg | Efruxifermin 50 mg |
|---|---|---|---|
| Change from baseline in liver stiffness measurement (LSM, kPa) at Week 24 | -0.8 ± 0.88 | -2.9 ± 0.93 | -4.2 ± 0.95 |
| Change from baseline in liver stiffness measurement (LSM, kPa) at Week 96 | -0.6 ± 0.98 | -4.0 ± 1.09 | -7.2 ± 1.08 |
Collected over 96 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/43 (0%) | 4/43 (9.3%) | 42/43 (97.7%) |
| Efruxifermin 28 mg | 0/40 (0%) | 4/40 (10%) | 38/40 (95%) |
| Efruxifermin 50 mg | 0/43 (0%) | 7/43 (16.3%) | 43/43 (100%) |
| Event | Placebo | Efruxifermin 28 mg | Efruxifermin 50 mg |
|---|---|---|---|
| GastritisGastrointestinal disorders | 0/43 | 1/40 | 0/43 |
| PancreatitisGastrointestinal disorders | 0/43 | 1/40 | 0/43 |
| Arteriospasm coronaryCardiac disorders | 0/43 | 1/40 | 0/43 |
| ankle fractureInjury, poisoning and procedural complications | 0/43 | 1/40 | 0/43 |
| Lower limb fractureInjury, poisoning and procedural complications | 0/43 | 1/40 | 0/43 |
| Panic attackPsychiatric disorders | 0/43 | 1/40 | 0/43 |
| Esophagitis ulcerativeGastrointestinal disorders | 0/43 | 0/40 | 1/43 |
| Pancreatitis, necrotizingGastrointestinal disorders | 0/43 | 0/40 | 1/43 |
| Non-cardiac chest painGeneral disorders | 1/43 | 0/40 | 1/43 |
| chest painGeneral disorders | 0/43 | 0/40 | 1/43 |
| Event | Placebo | Efruxifermin 28 mg | Efruxifermin 50 mg |
|---|---|---|---|
| DiarrheaGastrointestinal disorders | 13/43 | 23/40 | 19/43 |
| NauseaGastrointestinal disorders | 13/43 | 16/40 | 19/43 |
| COVID-19Infections and infestations | 13/43 | 10/40 | 16/43 |
| injection-site erythemaGeneral disorders | 8/43 | 10/40 | 8/43 |
| Increased appetiteMetabolism and nutrition disorders | 3/43 | 8/40 | 10/43 |
| Frequent bowel movementsGastrointestinal disorders | 1/43 | 9/40 | 0/43 |
| VomitingGastrointestinal disorders | 7/43 | 8/40 | 8/43 |
| Injection-site bruisingGeneral disorders | 7/43 | 8/40 | 6/43 |
| Procedural painInjury, poisoning and procedural complications | 7/43 | 8/40 | 5/43 |
| HypertensionVascular disorders | 1/43 | 8/40 | 5/43 |
Randomly assigned to groups
| Age, Categorical(Participants) | Placebo | Efruxifermin 28 mg | Efruxifermin 50 mg | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 34 | 31 | 37 | 102 |
| >=65 years | 9 | 11 | 6 | 26 |
| Age, Continuous(years) | Placebo | Efruxifermin 28 mg | Efruxifermin 50 mg | Total |
|---|---|---|---|---|
| Mean | 55.0 ± 10.1 | 56.5 ± 9.3 | 52.4 ± 11.4 | 54.7 ± 10.4 |
| Sex: Female, Male(Participants) | Placebo | Efruxifermin 28 mg | Efruxifermin 50 mg | Total |
|---|---|---|---|---|
| Female | 27 | 29 | 23 | 79 |
| Male | 16 | 13 | 20 | 49 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | Efruxifermin 28 mg | Efruxifermin 50 mg | Total |
|---|---|---|---|---|
| Hispanic or Latino | 15 | 17 | 20 | 52 |
| Not Hispanic or Latino | 28 | 25 | 23 | 76 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Placebo | Efruxifermin 28 mg | Efruxifermin 50 mg | Total |
|---|---|---|---|---|
| Race — White | 39 | 38 | 41 | 118 |
| Race — Black or African American | 2 | 1 | 1 | 4 |
| Race — Asian | 2 | 3 | 0 | 5 |
| Race — Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Race — American Indian or Alaskan Native | 0 | 0 | 0 | 0 |
| Race — Other | 0 | 0 | 1 | 1 |
| Region of Enrollment(participants) | Placebo | Efruxifermin 28 mg | Efruxifermin 50 mg | Total |
|---|---|---|---|---|
| United States | 43 | 42 | 43 | 128 |
| Baseline Fibrosis Stage(Participants) | Placebo | Efruxifermin 28 mg | Efruxifermin 50 mg | Total |
|---|---|---|---|---|
| Fibrosis stage 2 | 13 | 15 | 16 | 44 |
| Fibrosis stage 3 | 30 | 27 | 27 | 84 |
| Weight(kg) | Placebo | Efruxifermin 28 mg | Efruxifermin 50 mg | Total |
|---|---|---|---|---|
| Mean | 107.6 ± 25.6 | 103.9 ± 22.7 | 102.8 ± 21.1 | 104.8 ± 23.2 |
1 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Feb 2021 to primary completion in May 2024, 38 months.
Results were first posted in May 2025, 1 year after primary completion.
Of 132 industry-sponsored phase 2 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 30. This study's 38 months is above that.
Counting every sponsor, half of 185 studies reached it within 26 months; a quarter within 16 and three quarters within 36.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Efruxifermin
Non-alcoholic Fatty Liver Disease →